News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
The protease-activated Cas9 enzymes could reduce off-target effects and could be used to sense pathogens and trigger an immune response.
GreenLight Biosciences is using a proprietary cell-free RNA production technology to develop RNA-based products for the agricultural market.
The partners will work to find novel proteins, including DNA endonucleases, to develop new gene editing therapies for cystic fibrosis and other diseases.
Ohio State University researchers found that a phosphorothioate-modified DNA-crRNA duplex completely blocked the function of Cas12a.
The firm is developing and beta-testing a line of guide RNA libraries to support CRISPR-based targeted capture and sequencing approaches.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.
This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.